2014 Annual Report
Transcription
2014 Annual Report
2014 annual report Research, patient care and innovation to the benefit of the patient Together, let’s beat cancer. www.institut-curie.org CONTENTS P03 EDITORIAL P04 ABOUT THE INSTITUTE P06 HIGHLIGHTS P08 RESEARCH P10 PATIENT CARE P12 ADVANCED TRAINING P14 CONSERVING SCIENTIFIC HERITAGE P16 ACKNOWLEDGEMENTS P17 FUNDING MODEL CREDITS P18 INSTITUT CURIE PRESIDENT’S OFFICE FINANCIAL INFORMATION AUGUST 2015 – PHOTO CREDITS: ÉRIC BOUVET, AND FINANCIAL MANAGEMENT DEPARTMENT – OLIVIER COCHET-ESCARTIN, CHRISTOPHE HARGOUES, ALEXANDRE LESCURE, PEDRO LOMBARDI, NOAK/LE BAR FLORÉAL, BENOÎT RAJAU, THIBAUT VOISIN/INSTITUT CURIE – DESIGN AND PRODUCTION: ALL CONTENTS – CONTENT: ALL CONTENTS – PRINTING: ALL CONTENTS – PRINTED WITH VEGETAL INK ON PAPER FROM SUSTAINABLY MANAGED FORESTS COMPLIANT WITH ENVIRONMENTAL STANDARDS. 2 - ANNUAL REPORT 2014 - INSTITUT CURIE • EDITORIAL • EDITORIAL 2014 A PREPARATORY YEAR FOR THE 2015-2020 PROJECT I n 2014, the first year of my term, we focused on three major projects: balancing the Hospital Group budget, implementing recommendations from the French Court of Auditors, and, above all, planning for our future and our new project. Following a projected deficit of €10 million in 2014, we are now on track to balance the Hospital Group budget in 2015 thanks to the efforts of all employees and the yearlong push for structural reform. The Court of Auditors confirmed that we had used public donations appropriately, while also suggesting improvements to governance and organization. I have followed two guiding principles since my arrival: transparency with the Board of Directors and ringfencing funding. We also worked with all stakeholders to develop our 2015-2020 project, which refocuses our efforts on the key field of cancer biology. In the pioneering, humanist spirit of Marie Curie, another main theme of the project is openness towards partners and patients alike. Together we have laid the groundwork for the MC21 Project, which will enable us to become a major cancer center combining excellence in research and innovative treatments available to all. Our aim is to uphold the legacy of the Curie family while reinventing the treatment-research model that they pioneered. The institute has always been adept at delivering scientific discoveries to patients, an achievement made possible by its employees, partners and by the generosity of its donors and corporate patrons, to whom we express our gratitude. PROF. THIERRY PHILIP PRESIDENT 3 ABOUT THE INSTITUTE RESEARCH, TREAT, TRAIN AND CONSERVE Created on the basis of the « basic research to innovative care » model originally devised by Marie Curie, Institut Curie operates one of the largest cancer research centers in Europe and a leading-edge hospital group that treats all types of cancer, including breast, eye and childhood cancer, as well as the rarest forms of the disease. INTERNATIONALLY RENOWNED RESEARCH AND TREATMENT Institut Curie effectively combines international multidisciplinary research with excellence in cancer medicine. The Research Center spearheads innovation in all aspects of cancer research, from the fundamental mechanisms related to the growth of the disease, to emerging diagnosis techniques and therapeutic approaches. Treatment is provided at the Hospital Group, a pioneer in precision medicine that cares for patients diagnosed with all types of cancer. THE PAST, PRESENT AND FUTURE OF SCIENCE Training provides a means for Institut Curie to attract top talent and cultivate the level of expertise required to secure the future of innovation in the foundation’s research laboratories and hospital. The institute also helps pass on the history of science and the Curie family in particular, through the Curie Museum and its collections. THE INSTITUTE’S FOUR MISSIONS 01 RESEARCH Fighting cancer through a combination of transdisciplinarity, medical and scientific potential, and innovation. 03 ADVANCED TRAINING Spreading knowledge that advances science and treatment. 4 - ANNUAL REPORT 2014 - INSTITUT CURIE 02 PATIENT CARE Making patients the top priority to ensure they receive comprehensive care and tailored treatment. 04 CONSERVATION OF SCIENTIFIC HERITAGE The Curie Museum is a repository for the history of the Curie family and the foundation’s illustrious historical roots. • ABOUT THE INSTITUTE • KEY FIGURES 14,300 active patients 77 nationalities represented among the Institut Curie staff 1ST in breast cancer surgery (Ranking compiled by Notre Temps magazine in partnership with L’Express) 507 medical and scientific 3,300 Employees articles published in leading international journals (2014 inCities figures) (Hospital: 2,200 – Research: 1,100) doctors, researchers, caregivers, students, administrative and technical staff 83 More than 1,000 students and postdoctoral researchers worked at the institute in 2014 research teams 34 private-sector partners 204 CLINICAL STUDIES 900 volunteers 5 HIGHLIGHTS 2014 HIGHLIGHTS Radiation biology & Chemistry, cell signaling and cancer Radiotherapy “flashes” to reduce side effects Treating hard and fast seems to be a good way to limit the side effects of radiotherapy. This is the discovery made by researchers at Institut Curie, Inserm and the Vaud University Hospital, published in Science Translational Medicine. Most equipment currently in use is not powerful or accurate enough for this technique, but the device being installed at the Institut Curie Proton therapy center will open the door to a pre-clinical trial. HOPE BLOSSOMS A Daffodil for Curie Hope blossomed throughout France during the 10th annual A Daffodil for Curie charity event. 320 walkers and runners, 200 volunteers, companies, institutional partners, media outlets and a large number of donors all helped support the event, which collected €220,000. RADIOTHERAPY CUTTING-EDGE TECHNICAL FACILITIES In Saint-Cloud, the institute added two new machines at its radiotherapy facilities: Truebeam™ and Novalis™. The facilities were already among the most comprehensive in Europe, offering tomotherapy in Paris and proton therapy in Orsay. The precision of the new equipment will enable the institute to perform hypofractionated and stereotactic treatments (or “radiosurgical” procedures), as well as to expand its treatment indications. 6 - ANNUAL REPORT 2014 - INSTITUT CURIE • HIGHLIGHTS • COLLABORATIVE RESEARCH CELL MIGRATION: THE ART OF CHOOSING A GOOD LEADER Collaborative research by physicists and biologists at Institut Curie has found that migrating cells, which maintain strong interactions, designate one cell in the group to be the leader, which all the others follow. In an article published in Nature Cell Biology, the researchers explained that this kind of collective cell migration often occurs during the initial development of numerous tumors. INTERNATIONAL The institute exports its expertise to China Institut Curie took part in a three-day training program in Wuhan conducted by Immunocan, a joint Chinese and European consortium, and the Sino-French School of Oncology. During the program, 80 young professionals learned the fundamentals of oncology. HONOR Geneviève Almouzni wins Grand Prix award Fondation pour la Recherche Médicale (FRM) awarded its Grand Prix honor to Research Center director Geneviève Almouzni, PhD, for her exceptional contribution to medical knowledge and understanding of genomic organization. 7 RESEARCH 01 INNOVATIVE, INTERDISCIPLINARY RESEARCH “Promoting cutting-edge research at the Institut Curie Research Center – an internationally recognized organization in the fight against cancer – requires a combination of effective, interdisciplinary collaboration, the influx of new ideas that comes from supporting young researchers, and the knowledge sharing that results from the reach of our work both in France and abroad.” Geneviève Almouzni, PhD DIRECTOR OF THE RESEARCH CENTER R esearchers at Institut Curie are making promising new discoveries through a cross-disciplinary approach that is improving knowledge of mechanisms that could lead to new forms of treatment. The foundation’s expert research teams published their findings throughout the year in leading international journals. BLOCKING THE GROWTH OF MEDULLOBASTOMA Medulloblastoma is the most common malignant brain tumor found in children and develops in the cerebellum. An “Investments for the Future” research team (CNRS/Inserm/Institut Curie) formed 8 - ANNUAL REPORT 2014 - INSTITUT CURIE in 2010 has discovered how the Atoh1 protein is regulated. This breakthrough, published in Developmental Cell, paves the way for new therapeutic approaches. The lead is all the more promising given that a number of drugs are already being tested. THE FIRST GLOBAL OVERVIEW OF YEAST GENE DELETION MUTANTS Geneticists recently identified possible causes for mutations in cancer cells by studying a normal wild strain and nine mutant strains of the yeast species Saccharomyces cerevisiae. These findings were published in PNAS and provide clues for identifying the human genes involved in cancer predisposition. The team is looking to collaborate with international partners to advance this research and devise early detection and treatment techniques. COLON CANCER: TWO GENETIC ALTERATIONS THAT CAUSE METASTASIS One of the major challenges in colon cancer treatment is successfully treating the disease when metastases are present. A group of biologists, bioinformaticians and doctors joined forces to describe—both theoretically and experimentally— the combination of two genetic alterations responsible for tumor growth, in the journal Nature Communications. In addition to providing insight into tumor progression, the model of colon cancer developed by the team can be used to test new therapies that block metastasis. In 2014, the institute sought to give fresh impetus to multi-scale physics, chemistry and biology research by creating the Chemical Biology of Membranes and Therapeutic Delivery laboratory (CNRS/Inserm/Institut Curie) led by Inserm Research Director Ludger Johannes, PhD. The laboratory works to discover new therapeutic approaches. 83 teams WORKING IN PARTNERSHIP WITH CNRS, Inserm and universities VIEWPOINT A series of validation milestones mark the transition from basic research to the pharmaceutical industry. “What is extraordinary about Institut Curie is that we have the full range of competencies required to take the process from start to finish. I’m responsible for developing applications based on discoveries as quickly as possible, working with both internal and external stakeholders.” NATHALIE AMZALLAG, PHD, Research Engineer and Project Manager, Cancer Immunotherapy 9 • RESEARCH • HOW THE SHIGA TOXIN CROSSES THE CELLULAR THRESHOLD How do cells ingest pathogenic agents bound to their surfaces in order to trigger an intracellular response? Biologists used the Shiga toxin, a pathogenic agent produced by intestinal bacteria, and a minimal model membrane system designed in collaboration with biophysicists, to advance their understanding of this cell entry mechanism. They detailed this new stage in an unconventional endocytosis mechanism in Nature. The fundamental knowledge they uncovered could help find mechanisms for transporting medicine in certain cells, inducing an anti-tumoral or anti-viral immune response, or even giving false “orders” to tumor cells. PATIENT CARE 02 PERSONALIZING PATIENT CARE “Our priority is to ensure patients are the central focus of all our activities, to ensure they receive care with a resolutely human touch. We also offer increasingly innovative techniques in surgery and chemotherapy as well as radiotherapy, an area of excellence for the institute since its inception.” DR. MARC ESTÈVE, DIRECTOR OF THE HOSPITAL GROUP T he institute continually reassesses its methods and innovates in order to provide patients with the best possible care. One major change in 2014 was the rise in prominence of outpatient surgery, which was met with approval by patients. The researchers also made significant advances in understanding tumors, in particular through a large-scale trial with over 700 participants and research on circulating tumor cells. OUTPATIENT SURGERY TAKES ON CENTRAL ROLE While the institute has performed ambulatory surgery since the 1970s, the creation of a dedicated outpatient unit in 2012—primarily for breast cancer 10 - ANNUAL REPORT 2014 - INSTITUT CURIE treatment—ushered in a new era for both patients and caregivers. The proportion of outpatient procedures for breast cancer at the institute shot up from 15 to 50% over the course of 2 years. Over 90% of patients expressed satisfaction with their treatment and operating room procedures in a questionnaire conducted one year after the outpatient unit opened. The results of the survey were presented at the institute’s first conference on the theme “Breast cancer and outpatient surgery – Patients, caregivers and new methods of organizing treatment,” held on September 26, 2014. The event provided a forum for topics related to therapeutic care: the current situation in France and the outlook for future development, as well as hospitality and safety of care. SHIVA TRIAL: FROM CONCEPT TO REALITY The SHIVA trial stands among the institute’s seminal clinical research projects, with more than 700 patients taking part. An innovative example of precision medicine, the trial proved that it was possible to develop a genetic map of a patient’s tumor in less than four weeks, in order to provide pinpoint treatment. The project also demonstrated the effectiveness of taking an interdisciplinary approach and fostering a close working relationship between doctors, patients, biological-platform researchers and engineers, non-medical caregivers and clinical research staff. PROTON THERAPY: EXTENDING INDICATIONS Proton therapy is an ultra-precise form of radiotherapy that treats tumors while limiting irradiation in adjacent tissue. Formerly reserved for intracranial tumors, this radiotherapy technique is now available to patients with extracranial tumors. MORE THAN 2,200 PATIENTS TOOK PART IN CLINICAL STUDIES VIEWPOINT “Following the documentary Healing Our Perceptions: Rebuilding Life After A Mastectomy, Institut Curie’s Info-Sein group produced a web documentary available online for women coping with a surgical ablation in the breast after cancer. Its aim is to guide patients and their loved ones as they find their own path to surgical or other forms of reconstruction—a step that isn’t always covered by oncologists.” DR. SÉVERINE ALRAN, Surgical Oncologist, Head of the Outpatient Surgery Unit 11 • PATIENT CARE • CIRCULATING TUMOR CELLS: A NEW SURVIVAL INDICATOR Research on circulating tumor cells is expected to make a major impact on early diagnosis of relapses, personalized treatment and assessment of treatment effectiveness. At Institut Curie, doctors are demonstrating how these cells provide additional information for the prognosis of patients who have metastatic cancer. In March 2014, the prestigious journal The Lancet Oncology published the foundation’s overview of all the studies on this type of cancer conducted in Europe. ADVANCED TRAINING 03 ADVANCED TRAINING: INVESTING IN THE FUTURE “The main aims of the institute’s Training Unit are to use the international reach of our programs to promote the exchange of ideas and the emergence of new lines of research, to work with students to promote their research work, and to further develop courses that build stronger ties between research and the hospital.” Graça Raposo, PhD DEPUTY DIRECTOR OF ADVANCED TRAINING AT THE RESEARCH CENTER “The missions of the Training Unit at Institut Curie are to teach fundamental and translational research to as many young doctors as possible, to help develop medical and scientific careers by offering positions in renowned laboratories, and to leverage our expertise through the development of specific training.” PRof. Roman Rouzier, DEPUTY DIRECTOR OF TRAINING AT THE HOSPITAL GROUP PROFESSOR OF SURGERY AT THE UNIVERSITY OF VERSAILLES SAINT-QUENTIN 12 - ANNUAL REPORT 2014 - INSTITUT CURIE T SARAH WATSON, DOCTOR AND RESEARCHER Since 2010, Institut Curie has awarded scholarships to interns, assistants and pharmacists seeking to carry out science theses at the Research Center or Department of Translational Research. Following a selection process, Sarah Watson began her science thesis at the Institut Curie/Inserm/Paris Descartes University Genetics and Cancer Biology Unit. Her work pertains to the study of genetic anomalies associated with the Ewing family of sarcomas— bone cancer found in children and adolescents— Founding member of 242 PhD students in science and aims to provide doctors with more prognostic tools to guide their therapeutic choices. The scholarship represents an excellent opportunity and compares very favorably with others of the same type. A graduate in both biology and medicine specializing in oncology, Sarah completed several internships in various Institut Curie research laboratories. During her time at the foundation, Sarah had access to the cutting-edge technical equipment and dedicated staff that have earned Institut Curie a reputation as a paragon of excellence. 250 14,500 medical students AND INTERNS HOURS OF TEACHING VIEWPOINT “I first learned about palliative care during my internship at the institute and found this humanist approach to medicine very appealing. Learning from the skilled, articulate team at Institut Curie was an eye-opening experience that helped me strike the right balance between general medicine and my desire to work as part of a team.” DR. LAURE PERCHERON, former Institut Curie intern and doctor in the palliative care department at Poitiers University Hospital 13 • ADVANCED TRAINING • he Training Unit at Institut Curie is a team dedicated to managing, organizing and promoting the institute’s advanced training mission. The unit offers a wide variety of courses—technical, multidisciplinary, international, general and more— in an environment highly conducive to learning. Young researchers and doctors gain invaluable experience working in state-of-the-art facilities, enabling them to pursue fulfilling scientific and medical careers. CONSERVING SCIENTIFIC HERITAGE 04 THE CURIE MUSEUM TH CELEBRATES ITS 20 ANNIVERSARY “The Curie Museum and archives are more than just a landmark or history museum—the site is now a space for sharing and spreading knowledge. The museum’s unique collections retrace the history of the family with five Nobel Prizes and the broader scientific and social developments of the interwar period.” Renaud Huynh DIRECTOR OF THE MUSEUM UNIT AND THE CNRS/ INSTITUT CURIE INSTITUT DU RADIUM ARCHIVES E stablished in 1994 by CNRS and Institut Curie, the Curie Museum has become a nexus for knowledge production and sharing that contributes to France’s international renown and excellence in the fields of science and medicine. The primary missions of the museum are to: • Safeguard, collect and conserve the history of the Curie family and their associates, Institut du Radium and the Curie Foundation, as well as radium and radioactivity in general • Curate and classify the collections, develop tools to improve access and study, contribute to social science research • Promote, exhibit and share the collections with the widest possible audience 14 - ANNUAL REPORT 2014 - INSTITUT CURIE Bringing the memory of the Curie family to life is a means of transmitting the history and values of these exceptional individuals while extending the cultural reach of science. The origins of the Curie Museum are found in the collections it houses, in particular two historic rooms—Marie Curie’s office and laboratory—that were restored to their original state in the 1960s. This historical landmark exhibits a vast array of exceptional pieces—scientific instruments, furniture, photos, books, documents and other items—that have drawn a wide audience of captivated visitors from across the world for over 50 years. A guardian of collective memory and a repository for unique scientific and cultural heritage, MARIE CURIE AND THE GREAT WAR The First World War centenary in 2014 provided an ideal opportunity to honor the medical radiology work of Marie Curie and her daughter Irène during the conflict, as well as to highlight the pioneering role played by Dr. Claudius Regaud, founder of the cancer research centers. Over the course of the year, the museum’s historical resources center opened its archives to filmmakers, who produced a well-received documentary drama on Marie Curie’s work during the war. The museum also partnered with a theater company to produce a similarly themed stage production. WOMEN IN SCIENCE: MARIE CURIE’S HEIRS Research at the museum focuses on two main topics: the scientific and medical history of Institut du Radium and the Curie Foundation, and the historic role of women in science and medicine. The work of Natalie Pigeard-Micault, PhD, CNRS engineer and head of the museum’s historical resources center, inspired an open-air exhibition celebrating women in science who have followed in Marie Curie’s footsteps, held from March to October. The exhibition profiled 25 scientists from the past and 18 current Institut Curie experts, offering a detailed look at both pioneering women in the scientific community and the women who are currently shaping science and medicine. Dr. Pigeard-Micault, a recognized authority on the history of women in science in the 19th and 20th centuries, also organized a number of conferences on the topic throughout the year. A NEXUS FOR KNOWLEDGE PRODUCTION AND SHARING Nearly 12,500 people visited the museum in 2014 and specialist requests increased tenfold, thanks to efforts to share historical resources with a greater audience. The institution also added a free app to its array of digital communication tools, enhancing the visitor experience and complementing the numerous events held throughout the year for people of all ages: theme-based tours, demonstrations, documentary films, etc. • CONSERVING SCIENTIFIC HERITAGE • the museum—housed in the former Institut du Radium, which became Institut Curie in the 1970s—has since grown to become a nexus for knowledge production and sharing. Nearly 12,500 VISITORS IN 2014 VIEWPOINT “The museum is a monument to the history of chemistry and physics, as well as a tremendous homage to Marie Curie and the pioneers of radioactivity, who used their discoveries to further science and healthcare. Bravo!” CHRISTOPHER CLEMENT, Scientific Secretary, International Commission on Radiological Protection 15 ACKNOWLEDGEMENTS THANK YOU TO OUR 180,000 DONORS TO THE 95 PEOPLE WHO CHOSE TO DONATE PART OR ALL OF THEIR WEALTH VIA A LEGACY GIFT, DONATION OR LIFE INSURANCE POLICY TO OUR PRIVATE-SECTOR PARTNERS AG2R La Mondiale, Agence Nationale des Chèques Vacances, AstraZeneca, Audap & Mirabaud, Bioderma, CEW, CNH Industrial, Conseil National des Centres Commerciaux, Crédit Suisse, Fédération Française de Rugby, Fondation Apicil, Fondation Areva, Fondation Dominique et Tom Alberici, Fondation EDF, Fondation Eric Vincenot, Fondation GDF SUEZ, Fondation Hôpitaux de Paris – Hôpitaux de France, Fondation L’OCCITANE, Fondation L’Oréal, Fondation MACSF, Fondation Michelin, Fondation Philanthropia, Fondation Swiss Life, Fondation Truffaut, GDF Suez, Hôtel des ventes Drouot, Malakoff Médéric, Mutuelle Bleue, Nikon, Pause Fruitée, The Annenberg Foundation, The Conny Maeva Charitable Foundation, Thornburg Foundation and Truffaut, to our public-sector partners CNRS, European Commission, French Ministry of National Education, Higher Education and Research, French Ministry of Social Affairs, Health and Women’s Rights, INCa, Inserm, local and regional authorities, PSL Research University Paris, Unicancer and universities 16 - ANNUAL REPORT 2014 - INSTITUT CURIE FUNDING MODEL A STRONG FUNDING MODEL Institut Curie benefits from a diverse array of revenue sources, affording the foundation the level of independence required to undertake innovative programs. activities in partnership with fellow research organizations, which pay a portion of the personnel, operating and investment costs. In addition, the Research Center receives an annual basic research subsidy from France’s higher education and research ministry. Further funds are generated from competitive national and international calls for tender issued by France’s Investments for the Future program, the European Research Council and other institutions. The institute’s research programs also rely on private-sector partners and the generosity of the public. Each year, Institut Curie makes a major effort to collect the resources required to perform and develop its missions from this diverse group of financial backers. For its part, the Curie Museum is financed by CNRS and public donations. €324.2 M €41.8 M total resources 180,000 DONORS resources from private donors and LEGACY GIFTS 17 • ACKNOWLEDGEMENTS & FUNDING MODEL • T he Hospital Group is a private healthcare establishment recognized as serving the public interest. As a result of this status, the institute’s treatment, clinical research, teaching and innovation activities are primarily funded by the French social security system. This revenue is supplemented by income from other sources, such as billing for patients not covered by social security, out-of-pocket payments and outpatient day rates. The Hospital Group also receives clinical research and innovation funding from industrial companies, patrons, charitable organizations, public and semi-public organizations, and the generosity of the public. The Research Center operates based on a very different funding model. The center develops FINANCIAL INFORMATION FINANCIAL INFORMATION 2014 was a decisive year for Institut Curie in many respects. Strategic planning aimed at positioning the foundation as a major stakeholder in 21st century cancer research and treatment resulted in the Board of Directors approving medical and scientific projects and the medical-scientific program that form the core of our Corporate Project. The translational research teams relocated to the Hospital Group, increasing interactions between doctors and researchers, which in turn furthered the research-care continuum. And the number of donors and testators who supported the institute in our fight against cancer increased yet again. We would like to offer all those who donated our deepest gratitude. Finally, with regard to asset management, we have expanded our investments as a result of the combined effect of positive cash flow and income from financial assets. ACCOUNTING BALANCE SHEET ASSETS (euros) 2014 2013 230,515,290 239,599,388 1- Subscribed capital unpaid 2- Fixed assets (2.1+2.2+2.3) 2.1- Intangible fixed assets 2.2- Tangible fixed assets 2.3- Financial assets 3- Current assets (3.1+3.2.1+3.2.2+3.3+3.4) 1,555,485 1,535,670 218,798,225 228,160,542 10,161,580 9,903,176 244,593,650 241,195,160 4,475,379 3,973,723 162,770,836 164,661,756 3.2.2- Debtors due after one year 55,550,000 55,652,822 3.3- Cash at bank and in hand 21,088,040 15,836,179 3.1- Stocks 3.2.1- Debtors due within one year 3.4- Other current assets Total assets (1+2+3) 709,395 1,070,680 475,108,940 480,794,548 LIABILITIES (euros) 2014 2013 4. Capital and reserves (4.1+4.2+4.3+4.4) 285,552,570 279,857,763 4.1- Subscribed capital 170,261,653 167,385,797 4.2- Reserves 147,841,479 142,348,425 4.3- Profit and loss brought forward from the previous years -39,642,097 -34,409,886 4.4- Profit and loss brought forward for the financial year 5. Creditors (5.1.1+5.1.2+5.2.1+5.2.2) 5.1.1- Long term non-bank debt 5.1.2- Long term bank debt 5.2.1- Short term non-bank debt 5.2.2- Short term bank debt Total liabilities (4+5) 18 - ANNUAL REPORT 2014 - INSTITUT CURIE 7,091,535 4,533,427 189,556,370 200,936,785 0 0 34,999,000 39,145,578 150,236,306 156,689,418 4,321,064 5,101,789 475,108,940 480,794,548 INCOME STATEMENT Euros 2013 2014 Revenue 353,216,848.00 344,942,229.00 501,656 -150,931 Variation in stocks (1) Other operating income Operating income (OI) 0 0 353,718,504 344,791,298 Cost of materials and consumables 62,755,318 62,727,607 Other operating charges 96,845,083 95,390,049 153,578,343 155,090,835 Remuneration and charges (staff costs) Gross Operating Profit or Loss (GOP/GOL) 40,539,760 31,582,807 Depreciation and value adjustments on non-financial assets 31,904,043 32,292,005 Net Operating Profit or Loss (NOP/NOL) 8,635,717 -709,198 Financial income and value adjustments on financial assets 8,821,646 8,567,823 Interest paid 3,111,576 3,319,333 Similar charges 0 0 14,345,787 4,539,292 Extraordinary income 3,410,629 104,452 Extraordinary charges 10,664,881 110,317 7,091,535 4,533,427 Profit or Loss on ordinary activities Taxes on profits Profit or Loss for the financial year (Net result) (1) Positive or negative amount INCOME AND EXPENDITURE BY PUBLIC INTEREST ASSIGNMENT CARE Expenditure < 8 2%P ublic health insurance funds 1 2%O ther income Income < RESEARCH 78% on care activities, i.e., €229.1 million 5 6%Research contracts 22%on research, i.e., €65.6 million 2 6%P ublic fundraising 6% P ublic fundraising 14% Grant from the French Ministry of Research 4% O ther income H ospital operations, including clinical research Research activities 19 • FINANCIAL INFORMATION • Income A private charitable foundation since 1921 26 rue d’Ulm, 75248 PARIS CEDEX 05 – FRANCE Phone: +33 (0)1 56 24 55 00 Follow us on: Together, let’s beat cancer. www.institut-curie.org